Search Results - "Gianotti, N."

Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2) by Maggiolo, F, Gianotti, N, Comi, L, Di Filippo, E, Fumagalli, L, Nozza, S, Galli, L, Valenti, D, Rizzi, M, Castagna, A

“…Abstract Background We explored the combination of rilpivirine plus cobicistat-boosted darunavir [a two-drug regimen (2DR)] when switching from standard triple…”
Get full text

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum] by Ranzenigo, Martina, Gianotti, Nicola, Galli, Laura, Poli, Andrea, Mastrangelo, Andrea, Bruzzesi, Elena, Chiurlo, Matteo, Nozza, Silvia, Bossolasco, Simona, Spagnuolo, Vincenzo, Mancusi, Daniela, Termini, Roberta, Carini, Elisabetta, Lazzarin, Adriano, Castagna, Antonella

“…Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975-1982. Page 1975, Abstract, Results, line five, the text "the ongoing regimen was…”
Get full text

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study by Antinori, A, Rusconi, S, Gianotti, N, Bini, T, Mancusi, D, Termini, R

“…The protease inhibitor (PI) darunavir (DRV) has proven to be highly effective and well tolerated for HIV treatment. The DAD (Data collection on Adverse Effects…”
Get full text

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter? by Vergori, A., Gagliardini, R., Gianotti, N., Gori, A., Lichtner, M., Saracino, A., De Vito, A., Cascio, A., Di Biagio, A., Monforte, A. d'Arminio, Antinori, A., Cozzi-Lepri, A.

“…•Switching from tenofovir disoproxil fumarate (TDF)-containing regimens has increased considerably in recent years.•A high proportion of people with a…”
Get full text

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice by Ranzenigo, Martina, Gianotti, Nicola, Galli, Laura, Poli, Andrea, Mastrangelo, Andrea, Bruzzesi, Elena, Chiurlo, Matteo, Nozza, Silvia, Bossolasco, Simona, Spagnuolo, Vincenzo, Mancusi, Daniela, Termini, Roberta, Carini, Elisabetta, Lazzarin, Adriano, Castagna, Antonella

“…Background: The primary objective of this study was to estimate the proportion of people living with HIV (PLWH) who switched from a non-protease inhibitor…”
Get full text

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients by Gianotti, N., Canducci, F., Galli, L., Cossarini, F., Salpietro, S., Poli, A., Nozza, S., Spagnuolo, V., Clementi, M., Sampaolo, M., Ceresola, E.R., Racca, S., Lazzarin, A., Castagna, A.

“…In this single-centre, retrospective study, we analyzed data of 194 patients receiving antiretroviral therapy with <50 human immunodeficiency virus (HIV) RNA…”
Get full text

Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up by Gianotti, N., Galli, L., Salpietro, S., Cernuschi, M., Bossolasco, S., Maillard, M., Spagnuolo, V., Canducci, F., Clementi, M., Lazzarin, A., Castagna, A.

“…Human immunodeficiency virus (HIV) -infected patients with HIV RNA loads of < 50 copies/mL were followed-up for a median (interquartile range) of 30.8…”
Get full text

Number of daily pills, dosing schedule, self‐reported adherence and health status in 2010: a large cross‐sectional study of HIV‐infected patients on antiretroviral therapy by Gianotti, N, Galli, L, Bocchiola, B, Cahua, T, Panzini, P, Zandonà, D, Salpietro, S, Maillard, M, Danise, A, Pazzi, A, Lazzarin, A, Castagna, A

“…Objectives The aim of the study was to assess whether pill burden is associated with self‐reported adherence to current combination antiretroviral regimens and…”
Get full text

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption by Canducci, F., Barda, B., Ceresola, E., Spagnuolo, V., Sampaolo, M., Boeri, E., Nozza, S., Cossarin, F., Galli, A., Gianotti, N., Castagna, A., Lazzarin, A., Clementi, M.

“…The objective of this study was to address the evolution of human immunodeficiency virus type 1 (HIV-1) mutations resistant to the integrase inhibitor…”
Get full text

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors by Bracciale, L., Colafigli, M., Zazzi, M., Corsi, P., Meraviglia, P., Micheli, V., Maserati, R., Gianotti, N., Penco, G., Setti, M., Di Giambenedetto, S., Butini, L., Vivarelli, A., Trezzi, M., De Luca, A.

“…Objectives Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretroviral therapy. Patients and methods A retrospective analysis…”
Get full text

Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA) by Rusconi, S., Adorni, F., Bruzzone, B., Di Biagio, A., Meini, G., Callegaro, A., Punzi, G., Boeri, E., Pecorari, M., Monno, L., Gianotti, N., Butini, L., Galli, L., Polilli, E., Galli, M.

“…The prevalence of drug resistance associated with the failure of nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens and the predictors of…”
Get full text

Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen by A. Lazzarin, L. Galli, N. Galizzi, A. Castagna, N. Gianotti, M. Ripa, A. Andolina, S. Nozza, V. Spagnuolo, A. Poli

Get full text

Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy by Franzetti, M., Violin, M., Casazza, G., Meini, G., Callegaro, A., Corsi, P., Maggiolo, F., Pignataro, A.R., Paolucci, S., Gianotti, N., Francisci, D., Rossotti, R., Filice, G., Carli, T., Zazzi, M., Balotta, C.

“…We analysed the 12-week virological response to protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy in 1108 patients…”
Get full text

Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV‐infected patients by Gianotti, N, Visco, F, Galli, L, Barda, B, Piatti, P, Salpietro, S, Bigoloni, A, Vinci, C, Nozza, S, Gallotta, G, Lazzarin, A, Castagna, A

“…Objective As a proactive diagnosis of diabetes mellitus (DM) may prevent the onset of severe complications, we used an oral glucose tolerance test (OGTT) to…”
Get full text

Comparison of a Rule-Based Algorithm with a Phenotype-Based Algorithm for the Interpretation of HIV Genotypes in Guiding Salvage Regimens in HIV-Infected Patients by a Randomized Clinical Trial: The Mutations and Salvage Study by Gianotti, Nicola, Mondino, Vincenzo, Rossi, Maria Cristina, Chiesa, Elisabetta, Mezzaroma, Ivano, Ladisa, Nicoletta, Guaraldi, Giovanni, Torti, Carlo, Tarquini, Pierluigi, Castelli, Paula, Di Carlo, Aldo, Boeri, Enzo, Keulen, Wilco, Mc Kenna, Paula, Lazzarin, Adriano

“…Background. There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results. Methods. A…”
Get full text

Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients by Santoro, M. M, Bertoli, A, Lorenzini, P, Ceccherini-Silberstein, F, Gianotti, N, Mussini, C, Torti, C, Di Perri, G, Barbarini, G, Bini, T, Melzi, S, Caramello, P, Maserati, R, Narciso, P, Micheli, V, Antinori, A, Perno, C. F

“…Objectives: The protease inhibitor atazanavir (ATV) can be used either boosted by ritonavir (ATV300/r) or unboosted (ATV400). To date, however, genotypic…”
Get full text

Managing failure to antiretroviral drugs in HIV-1-infected patients by Gianotti, N, Lazzarin, A

“…Managing failure to antiretroviral therapies implies the addressing of several issues: the clinical stage, the virological and the immunological response to…”
Get more information

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone by Bongiovanni, M, Gianotti, N, Chiesa, E, Nasta, P, Cicconi, P, Capetti, A, di Biagio, A, Matti, A, Tirelli, V, Marconi, P, de Luca, A, Mussini, C, Gatti, F, Zaccarelli, M, Abeli, C, Torti, C, Antinori, A, Castagna, A, d'Arminio Monforte, A

“…We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245…”
Get full text

Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals by Soria, A, Gianotti, N, Cernuschi, M, Lazzarin, A

“…To assess the efficacy of 48 weeks' treatment with saquinavir 1600 mg and ritonavir 100 mg, both given once daily (SQVOD), in drug-experienced HIV-infected…”
Get more information

Hepatitis B surface antigen clearance and appearance of antibodies against hepatitis B surface antigen after treatment with recombinant interleukin 2 in a human immunodeficiency virus-infected patient by Gianotti, N, Uberti-Foppa, C, Boeri, E, Marinelli, M, Tambussi, G, Finazzi, R, Lazzarin, A

Get full text